Eif2B1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
eIF2B1 is the alpha subunit of the eukaryotic translation initiation factor 2B complex. The eIF2B heterodecamer consists of two copies each of five subunits (alpha, beta, gamma, delta, epsilon). The alpha subunit is the smallest and contributes to the structural organization of the complex. Crystal structures reveal the decameric arrangement with a central core formed by the regulatory subunits (alpha, beta, gamma, delta) and catalytic subunits (epsilon) at the periphery[@structure2015].
...
eIF2B1 Protein
Introduction
Eif2B1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
eIF2B1 is the alpha subunit of the eukaryotic translation initiation factor 2B complex. The eIF2B heterodecamer consists of two copies each of five subunits (alpha, beta, gamma, delta, epsilon). The alpha subunit is the smallest and contributes to the structural organization of the complex. Crystal structures reveal the decameric arrangement with a central core formed by the regulatory subunits (alpha, beta, gamma, delta) and catalytic subunits (epsilon) at the periphery[@structure2015].
The eIF2B complex serves as the guanine nucleotide exchange factor (GEF) for eIF2, catalyzing the exchange of GDP for GTP to regenerate active eIF2-GTP. This reaction is essential for translation initiation as the eIF2-GTP-Met-tRNAi ternary complex is required for start codon recognition at the ribosome[@eifb2018].
Normal Function
In the normal nervous system, eIF2B plays a critical role in regulating protein synthesis. The complex is particularly important in [neurons](/entities/neurons) and glia due to their high protein synthesis requirements for synaptic plasticity, neurotransmitter release, and myelin production. eIF2B is a key regulator of the integrated stress response (ISR), where cellular stress leads to phosphorylation of eIF2alpha, which allosterically inhibits eIF2B activity, reducing global translation while promoting expression of stress-response genes such as ATF4 and CHOP[@vwm2019].
In oligodendrocytes, eIF2B function is essential for myelination and white matter maintenance. The stress response regulation through eIF2B allows glial cells to adapt to metabolic demands and respond to cellular stress.
Role in Disease
Vanishing White Matter Disease (VWM)
Mutations in EIF2B1 cause vanishing white matter disease, an autosomal recessive leukodystrophy characterized by progressive cerebellar ataxia, spasticity, and deterioration of white matter. Pathogenic variants reduce eIF2B activity, impairing the integrated stress response in oligodendrocytes and [astrocytes](/entities/astrocytes). This makes glial cells vulnerable to various stresses, leading to myelin loss and cystic degeneration of white matter[@isrib2018].
The disease typically presents in early childhood with episodic deterioration triggered by minor infections or trauma. Neuropathologically, VWM shows diffuse rarefaction and cystic degeneration of cerebral white matter with relative preservation of neurons.
Therapeutic Targeting
Current therapeutic approaches for VWM focus on enhancing eIF2B activity:
ISRIB (Integrated Stress Response Inhibitor): A small molecule that stabilizes eIF2B and restores its activity despite eIF2alpha phosphorylation. ISRIB has shown promise in preclinical models of VWM[@therapeutic2021].
Guanabenz: An alpha-2 adrenergic agonist that was found to enhance eIF2B function and has been tested in VWM models[@oligodendrocyte2020].
Gene therapy: Approaches to deliver wild-type EIF2B1 to affected tissues are under investigation.
Key Publications
[Structure of the eIF2B decameric GEF complex (2015)](https://doi.org/10.1038/nature14888)
[eIF2B and mechanism of translational control (2018)](https://doi.org/10.1016/j.tibs.2018.04.004)
[VWM disease: pathophysiology and therapy (2019)](https://doi.org/10.1016/j.neuropharm.2019.107745)
[ISRIB rescues eIF2B activity in VWM models (2018)](https://pubmed.ncbi.nlm.nih.gov/29429891/)
[Therapeutic targeting of eIF2B in leukodystrophy (2021)](https://doi.org/10.1016/j.pharmthera.2021.107856)
[Oligodendrocyte vulnerability in VWM (2020)](https://doi.org/10.1002/glia.23899)
Background
The study of Eif2B1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.